ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors. Among individuals with ...
Patient-reported fatigue prior to cancer treatment could be used as a biomarker for identifying which individuals will develop serious or fatal adverse events.A retrospective analysis showed patients ...
Measuring treatment success in Sjögren's disease requires more than tracking systemic disease activity alone. Fatigue, pain, ...
The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...
Experts discuss the challenges of managing atopic dermatitis in real-world clinical practice, highlighting access barriers due to insurance disparities, the need for creative solutions to provide ...
Forbes contributors publish independent expert analyses and insights. Michael L. Millenson writes about healthcare as a skeptical optimist. An unusual study gives a new twist to the idea of ...
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback